2023年第2版NCCN肺癌筛查临床实践指南更新解读  

Updated interpretation of NCCN clinical practice guidelines for lung cancer screening, version 2.2023

作　　者：朱玲玲 伍娟[2] 王艇[1] 黄伟嘉 周清华[1] Zhu Lingling;Wu Juan;Wang Ting;Huang Weijia;Zhou Qinghua(Lung Cancer Center/Institute of Lung Cancer,West China Hospital,Sichuan University,Chengdu 610041,China;Outpatient Department,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院肺癌中心/肺癌研究所,四川成都610041 [2]四川大学华西医院门诊部,四川成都610041

出　　处：《实用肿瘤杂志》2023年第5期399-407,共9页Journal of Practical Oncology

基　　金：国家重点研发计划“政府间国际科技创新合作”重点专项(2016YEE0103400);国家自然科学基金项目(82202989);四川省科技厅区域合作项目(2021YFQ0029);四川大学华西医院横向项目(HX-H2105128,HX-H2112318,HX-H2204070)。

摘　　要：肺癌是全世界癌症相关死亡的主要原因,也是我国发病率和死亡率最高的恶性肿瘤。肺癌筛查是提高肺癌临床治愈率和改善肺癌预后的重要措施。2023年5月美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)更新发布2023年第2版NCCN肺癌筛查临床实践指南。该版指南基于高级别循证医学证据和最新的研究进展制定肺癌筛查标准,受到全世界临床医师的密切关注。本文将对新版指南主要更新内容进行解读,并与2022年第1版NCCN肺癌筛查指南进行比较,以期为我国现阶段肺癌筛查工作提供专业的循证医学建议和临床实践参考。Lung cancer is the leading cause of cancer-related death in the world,and it is also the malignant tumor with the highest incidence and mortality in China.Screening for lung cancer is an important measure to improve the clinical cure rate and prognosis of lung cancer.In May 2023,the National Comprehensive Cancer Network(NCCN)released the second edition of the 2023 NCCN clinical practice guidelines for lung cancer screening.This edition of the guidelines sets lung cancer screening criteria based on high-level evidence-based medical evidence and the latest research advances,and its update has received extensive attention from clinicians around the world.This article will interpret the main updates of the new version of the guidelines,and compare it with the first edition of the NCCN lung cancer screening guidelines in 2022,in order to provide professional evidence-based medical advice and clinical practice guidance for the current stage of lung cancer screening in China.

关 键 词：肺癌 筛查 NCCN指南 临床实践 更新解读 

分 类 号：R734.2[医药卫生—肿瘤]